ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "quality of life"

  • Abstract Number: 1344 • ACR Convergence 2021

    Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs

    Alexis Ogdie1, Robert McLean2, Maya Marchese2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Kevin Douglas5, Danny Quach5 and Philip Mease6, 1University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4AbbVie, North Chicago, IL, 5AbbVie Inc., North Chicago, IL, 6Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
  • Abstract Number: 1910 • ACR Convergence 2021

    Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial

    Laure Gossec1, Nemanja Damjanov2, Shigeyoshi Tsuji3, Apinya Lertratanakul4, Ralph Lippe5, Jayeshkumar Patel4, Patrick Zueger6 and Kurt de Vlam7, 1Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 2University of Belgrade School of Medicine, Institute of Rheumatology, Belgrade, Serbia, 3Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, 6AbbVie Inc., Mettawa, IL, 7Department of Rheumatology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium

    Background/Purpose: The achievement of disease control has been shown to be associated with improved prognosis in PsA, though no single measure of low disease activity…
  • Abstract Number: 0358 • ACR Convergence 2021

    Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey

    Uta Kiltz1, Kirsten Hoeper2, Ludwig Hammel3, Sebastian Lieb4, Andreas Haehle4 and Dirk Meyer-Olson5, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, 3Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, 4Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, 5m&i Fachklinik Bad Pyrmont, Hannover, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
  • Abstract Number: 0878 • ACR Convergence 2021

    Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression

    Eleni Papachristodoulou1, Loukas Kakoullis1, Savvas Psarelis2, Victor Hajiroussos3, Costas Christophi4 and Konstantinos Parperis1, 1University of Cyprus Medical School, Nicosia, Cyprus, 2Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, 3Ygia Polyclinic Hospital, Limassol, Cyprus, 4Cyprus University of Technology, Limassol, Cyprus

    Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
  • Abstract Number: 1347 • ACR Convergence 2021

    Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement

    Atul Deodhar1, Dafna Gladman2, Rebecca Bolce3, David Sandoval3, So Young Park3, Soyi Liu-Leage4, Peter Nash5 and Denis Poddubnyy6, 1Oregon Health & Science University, Portland, OR, 2Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Eli Lilly and Company, Indianapolis, IN, 4Eli Lilly and Company, Neuilly sur Seine, France, 5Griffith University, Brisbane, Australia, 6Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness indicative of axial involvement [1]. The prevalence of axial involvement varies between 25-70%…
  • Abstract Number: PP03 • ACR Convergence 2021

    Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
  • Abstract Number: 0373 • ACR Convergence 2021

    Self-monitoring of Disease Activity with a Smartphone App Is Feasible in Routine Clinical Management of Patients with Axial Spondyloarthritis – a Proof of Concept Study

    Uta Kiltz1, Robin Kempin1, Jutta Richter2, Anna Schlegel1, Xenofon Baraliakos1, Styliani Tsiami1, Bjoern Buehring1, David Kiefer3 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany

    Background/Purpose: Assessment and monitoring of disease activity and functioning is of major importance for qualified management of patients with axial spondyloarthritis (axSpA). This includes tight…
  • Abstract Number: 0891 • ACR Convergence 2021

    Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire

    Liza Rajasekhar1, Dhundra Bhavani1, Sneha Tota2, Vishnupriya Vijayalekshmi3, Ranjan Gupta4, Chengappa Kavadichanda5, Vineeta Shobha6, VirSingh Negi7 and Amita Aggarwal2, 1NIMS, Hyderabad, India, 2Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 3AIIMS, New delhi, delhi, India, 4AIIMS, New delhi, Ne Delhi, India, 5JIPMER, Pondicherry, India, 6Saint Johns Medical college, Bengaluru, Bengaluru, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

    Background/Purpose: Lupus quality of life (Lupus QoL) questionnaire is a disease specific patient reported outcome that is available in multiple languages1. Indian SLE inception cohort…
  • Abstract Number: 1392 • ACR Convergence 2021

    Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica

    Sebastian Sattui, Deanna Jannat-Khah, Lindsay Lally, Sarah Lieber, Lisa Mandl and Robert Spiera, Hospital for Special Surgery, New York, NY

    Background/Purpose: Frailty, a syndrome characterized by decreased physiologic reserve, is associated with chronic inflammation. We have shown a high prevalence of frailty in patients with…
  • Abstract Number: PP10 • ACR Convergence 2021

    Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words

    Noriko Okochi1, Eiji Oishi2 and Mika Ishiguro1, 1Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, 2Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan

    Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
  • Abstract Number: 0376 • ACR Convergence 2021

    Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort

    Imke Redeker1, Robert Landewé2, Désirée van der Heijde3, Sofia Ramiro4, Annelies Boonen5, Maxime Dougados6, Juergen Braun7 and Uta Kiltz7, 1German Rheumatism Research Centre (DRFZ), Berlin, Germany, 2Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 4Leiden University Medical Center, Leiden, Netherlands, 5Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, 6Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, 7Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic…
  • Abstract Number: 0925 • ACR Convergence 2021

    Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs

    Philip Mease1, Robert McLean2, Taylor Blachley2, Maya Marchese2, Laura Anatale-Tardiff3, Christopher Saffore4, Danny Quach5, Ana Biljan6 and Alexis Ogdie7, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4AbbVie, North Chicago, IL, 5AbbVie Inc., North Chicago, IL, 6Abbvie Inc., Chicago, IL, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
  • Abstract Number: 1451 • ACR Convergence 2021

    Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions

    Titilayo Ologhobo1, Bertilia Trieu2, Claudia Zurlini1, Bonnie McGrath1, Linda Roberts1, Vilma Briones1, Pamela Sanchez-Villagomez2, Robyn Wiesel1, Sandra Goldsmith1 and Laura Robbins1, 1Hospital for Special Surgery, New York, NY, 2Hospital of Special Surgery, New York

    Background/Purpose: According to the 2020 American Health Ranking System, 26% of adults are physically inactive with a higher prevalence found in adults ages ≥65 years.…
  • Abstract Number: PP13 • ACR Convergence 2021

    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

    Chantelle Marcial, Boston, MA

    Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
  • Abstract Number: 0402 • ACR Convergence 2021

    What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?

    Alain Lescoat1, Susan Murphy2, Yen Chen3, Nadia Vann1, David Cella4 and Dinesh Khanna3, 1Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2University of Michigan, Grosse Ile, MI, 3University of Michigan, Ann Arbor, MI, 4Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology